Cellular immunotherapies have revolutionized treatment of especially difficult-to-treat CD19 + hematological malignancies, and anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapies are commercially available from several companies. This evidence concerns the gene CD19 and hematologic disorder.